Portage (PRTG): Price-to-Revenue Ratio

Brandmark of Portage Biotech Corp (PRTG)

Portage Biotech Inc. relies on ESG principles and bioethics in drug development. The market capitalization-to-revenue ratio confirms this stability, with the metric capturing the current state. However, the company is currently cutting costs and preserving capital. The situation is further complicated by geopolitical barriers that are hindering international trials and disrupting the logistics of biomaterials.

PRTG Portage Biotech Inc. P/S Multiple (07/04/2022 - 11/13/2026)

Portage (PRTG) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price portagebiotech.com|PRTG - Price Target Chart
- stock exchange capitalization data:
Market Value Portage|PRTG - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Portage Biotech|PRTG - Book Capitalization|Market Value to Equity Ratio portagebiotech.com|PRTG - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Portage Biotech Inc.|PRTG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Portage Biotech Corp|PRTG - Company Total Debt|Debt to Book Capital Portage|PRTG - Company Long-Term Debts|Company Short-Term Loans and Borrowings Portage Biotech|Immediate Liquidity portagebiotech.com
- earnings and multiples data:
PRTG - Company Net Income|Expected Net Income Portage Biotech Inc.|PRTG - P/E Multiple|Forward P/E Multiple Portage Biotech Inc|PRTG - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Portage|PRTG - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Portage Biotech|PRTG - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months portagebiotech.com|PRTG - Earnings per share growth in current year|Expected net earnings per share growth next year Portage Biotech Inc.
- issuer revenue and sales details:
PRTG - Company Revenue|Company Future Revenue portagebiotech.com|PRTG - Market Cap to Revenue|Price to Expected Revenue Ratio Portage
Summary company analytics:portagebiotech.com
Mass-produced product of Portage Biotech Corp

The P/S ratio determines the market value of one dollar of sales, allowing for an assessment of the extent to which investor expectations are inflated relative to the business's current cash flows. Analyzing the market cap-to-revenue ratio of Portage Biotech Inc. (PRTG) reveals that the high valuation is based not on current earnings, but on the potential success of clinical trials in immuno-oncology, making the stock's stability dependent on future licensing agreements.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio BCAB (BioAtla, Inc.)|LIXT: P/S Multiple|Price to Sales Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Revenue Ratio Cellectar Biosciences|BLRX: Market Capitalization-to-Revenue Ratio|P/S Multiple CANF|P/S Multiple aprea.com (APRE)|Price-to-Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Price-to-Sales Ratio|NCNA: Market Cap to Revenue|Price to Sales chimerix.com|Cyclacel (CYCC) - Price-to-Revenue Ratio|Price-to-Sales Ratio GTHX (G1 Therapeutics)|Price-to-Revenue Ratio Kronos Bio Corp|Price to Sales Kintara Pharma KTRA|Price-to-Revenue Ratio Oncternal Therapeutics (ONCT)